Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sarah Chamlin MD

Sarah L. Chamlin MD

Professor of Pediatrics and Dermatology, Northwestern University Feinberg School of Medicine; Attending Physician, the Ann and Robert H. Lurie Children’s Hospital of Chicago, specializing in Pediatric Dermatology, Chicago, Illinois

Dr. Sarah Chamlin is Professor of Pediatrics and Dermatology at Northwestern University Feinberg School of Medicine and an attending physician at Lurie Children’s Hospital, specializing in pediatric dermatology.

Her clinical interests include hemangiomas (she is an active member of the Hemangioma Investigator Group) and other vascular lesions, hair and nails, and general pediatric dermatology. Her research interests include quality-of-life measurement in children and teens with skin disease and hemangiomas.

After receiving her medical degree from Rush Medical College in Chicago, Dr. Chamlin underwent residency training in pediatrics at Children’s Memorial Hospital in Chicago and in dermatology at the University of California, San Francisco. She completed her fellowship in pediatric dermatology at the University of California San Francisco Medical Center.

Disclosures

  • Consultant: Regeneron; Sanofi

Recent Contributions to PracticeUpdate:

  1. Safety of Prior Propranolol Therapy in Patients With Infantile Hemangioma
  2. Effects of Treatment With Tralokinumab on Clinical and Laboratory Indexes in Patients With Atopic Dermatitis
  3. Quality-of-Life Outcomes Associated With Dupilumab for the Treatment of Atopic Dermatitis in Young Children
  4. Outcomes of Treatment With Tralokinumab in Dupilumab-Experienced and Dupilumab-Naïve Patients With Atopic Dermatitis
  5. Risk of Acute Upper Respiratory Infections in Patients With Atopic Dermatitis Treated With Dupilumab vs Non-Targeted Immunosuppressants
  6. Dupilumab Induces Hair Regrowth in Pediatric Patients With Alopecia Areata and Concomitant Atopic Dermatitis
  7. Safety and Efficacy of Dupilumab in Children With Atopic Dermatitis Aged 6 Months to 5 Years
  8. Neonatal Filaggrin Genetic Screening and Counseling to Prevent Atopic Dermatitis in High-Risk Infants
  9. Incidence of Adverse Events After Accelerated Propranolol Initial Dosing in Patients With Infantile Hemangioma
  10. Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders

Most Read This Week

Recently Updated